Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OptiNose Inc OPTN

Healthcare
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and... see more

Recent & Breaking News (NDAQ:OPTN)

Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018

GlobeNewswire May 7, 2018

Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania

GlobeNewswire March 15, 2018

Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights

GlobeNewswire March 13, 2018

Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018

GlobeNewswire March 6, 2018

Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress

GlobeNewswire February 27, 2018

Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee

GlobeNewswire February 22, 2018

Peter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania

GlobeNewswire February 20, 2018

Optinose to Present at the 2018 RBC Capital Markets Healthcare Conference

GlobeNewswire February 15, 2018

Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference

GlobeNewswire February 9, 2018

Optinose Announces $100 Million Debt Financing from Athyrium Capital Management

GlobeNewswire January 2, 2018

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors

GlobeNewswire December 11, 2017

Optinose to Present at BMO Capital Markets Prescription for Success Healthcare Conference

GlobeNewswire December 7, 2017

Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights

GlobeNewswire November 27, 2017

Optinose to Report Third Quarter 2017 Financial Results and Operational Highlights on November 27, 2017

GlobeNewswire November 20, 2017

Optinose to Present at Piper Jaffray Healthcare Conference

GlobeNewswire November 17, 2017

Optinose to Present at Jefferies 2017 London Healthcare Conference

GlobeNewswire November 8, 2017

Optinose Expands Leadership Team with Key Hires

GlobeNewswire October 30, 2017

Optinose (Nasdaq: OPTN) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire October 24, 2017

Optinose Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock

GlobeNewswire October 17, 2017